Finding More Targets for CAR-T Cells CAR-T cell therapy has successfully treated some patients with leukemia and lymphoma. Researchers are looking to expand the range of cancers that will respond to the therapy. by Kendall K. Morgan FORWARD LOOK For Cancer Researchers, Dogs Offer Clues to Help Kids Similarities between cancers create path for studying new treatments. by Cameron Walker Survivor Profile A Second Chance After the deaths of her sister and mother from cancer and a bout with osteosarcoma as a teenager, Court Simmons vowed to “do something amazing” with her life. Her goal is to be a pediatric oncology nurse. by Lindsey Konkel Get Involved! The Power of Helping Twelve-year-old cancer survivor Peter Zucca starts a foundation to give back to kids with cancer. by Leigh Labrie Survivor Profile Brewing a Business While getting their new coffee business off the ground, John and Pat Curry took John’s cancer treatment one step at a time. by Jen A. Miller Stranger in a Strange Land Cancer puts everyone in foreign territory, but those diagnosed with a rare form of the disease may feel the most lost without clear guidance toward the best care or support from other survivors. Four steps can help ease the way. by Rabiya S. Tuma Get Involved One Young Survivor Helping Another A teen who survived cancer is raising money to help others. by Yvonne Lee Cancer Talk Drug Delays Recurrence in People With Early-Stage Breast Cancer People who have inherited BRCA mutations and are at high risk for cancer recurrence may benefit from a PARP inhibitor. by Pamela Rafalow Grossman Open Medical Records: Pros and Cons Patients now have full access to their online medical records. What are the benefits and downsides? by Jen Tota McGivney Remote Care After adapting remote patient monitoring programs to cancer patients with COVID-19, cancer centers delve deeper into the programs’ value for cancer patients undergoing treatment. by Jon Kelvey Moving Away From the Maximum Tolerated Dose The FDA recently expressed a new commitment to testing cancer drugs at lower doses, rather than defaulting to the highest dose most people can tolerate. by Marcus A. Banks More Posts